Physician profile
Lora Waldman
NPI 1255657318
$2,430.41
in general payments reported to CMS, 2019-2025
34 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $651 · 2020: $262 · 2021: $579 · 2022: $613 · 2023: $327.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $327.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $326.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exeltis, USA INC. | $320.34 | 2020-2023 | Slynd |
| Therapeuticsmd, INC. | $318.27 | 2019-2022 | |
| Abbvie INC. | $316.76 | 2019-2023 | Liletta, Orilissa, Lo Loestrin Fe |
| Bayer Healthcare Pharmaceuticals INC. | $199.47 | 2019-2023 | |
| Allergan, INC. | $184.63 | 2019-2020 | |
| Myovant Sciences INC. | $117.42 | 2021-2022 | |
| Pfizer INC. | $94.31 | 2022-2023 | |
| Avion Pharmaceuticals | $88.09 | 2019-2023 | Balcoltra |
| Coopersurgical, INC. | $74.52 | 2019-2023 | Paragard T 380a |
| Organon LLC | $72.81 | 2022-2023 | Nexplanon |
| Lupin INC. | $66.21 | 2019 | |
| Evofem Biosciences, INC. | $52.32 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $41.84 | 2019-2020 | |
| Mayne Pharma Commercial LLC | $40.50 | 2023 | |
| Dysis Medical, INC. | $39.68 | 2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $37.40 | 2023 | Myfembree |
| Astellas Pharma US INC | $36.94 | 2019 | |
| Amag Pharmaceuticals, INC. | $31.18 | 2019-2020 | |
| Amgen INC. | $30.89 | 2020-2021 | |
| Novo Nordisk INC | $25.24 | 2019 | |
| Daiichi Sankyo INC. | $24.60 | 2019 | |
| Sage Therapeutics, LLC | $20.79 | 2022 | |
| Agile Therapeutics, INC. | $18.71 | 2021 | |
| Mylan Pharmaceuticals INC. | $18.17 | 2019 | |
| Renovia INC | $18.12 | 2021 | |
| Roche Diagnostics Corporation | $18.08 | 2021 | |
| Baxter Healthcare | $16.68 | 2019 | |
| Medicem INC. | $16.34 | 2020 | |
| Duchesnay USA Incorporated | $16.06 | 2019 | |
| Smith+Nephew, INC. | $15.73 | 2020 | |
| Vertical Pharmaceuticals, LLC | $15.61 | 2019 | |
| Trevena, INC. | $15.45 | 2021 | |
| Millicent US INC | $14.72 | 2020 | |
| Meditrina | $12.53 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lora Waldman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.